NLS Pharmaceutics + 200%

NLS Pharmaceutics (NASDAQ:NLSP) announces that it has entered into a License Agreement with Novartis Pharma AG, for all of the available data in the original NDA for Sanorex (mazindol) submitted to the U.S. FDA in February 1972

Share your opinion in the comments and support the idea with likes.
Thank you for your support!
Fundamental AnalysisTechnical IndicatorsNLSTrend Analysis

Хочешь хороших денег – умей выжидать
Also on:

Disclaimer